Listen

Johnson & Johnson

McKinsey & Company has reached a $573 million settlement with nearly 50 state governments as well as the District of Columbia and territories, over its role helping to market and boost sales of high-risk opioids including OxyContin.

Most of the funds will be devoted to paying for treatment and rehabilitation programs in communities devastated by the addiction crisis. As part of the settlement, McKinsey admits to no wrongdoing.

This deal heads off civil lawsuits threatened by state attorneys general.

Updated at 5:38 p.m. ET

Two coronavirus studies have been put on pause by drugmakers as they investigate safety concerns.

The pauses are not uncommon or cause for undue concern, but they highlight how little is known about the combination of medications prescribed to President Trump following his COVID-19 diagnosis.

Johnson & Johnson paused all clinical trials of its experimental COVID-19 vaccine after a study participant became sick with an "unexplained illness."

As drug firms race to position themselves as key players in the coronavirus fight, the industry faces a renewed wave of civil lawsuits stemming from its role in the nation's deadly opioid epidemic.

Thousands of cases that ground to a halt because of the COVID-19 pandemic are moving forward again as local, state and federal courts reopen around the United States.

Updated on Nov. 21 at 4 p.m. ET

A global megacorporation best known for Band-Aids and baby powder is now on the hook for about $107 million less than originally anticipated over its role in Oklahoma's opioid crisis.

In a judgment filed Friday, state District Judge Thad Balkman revised an earlier ruling against Johnson & Johnson and told the drugmaker to make a onetime payment of $465 million — not the $572 million he had originally ordered.

Updated at 5:37 p.m. ET

Confronted with a torrent of lawsuits across the U.S., several major drug companies are in discussions with authorities to resolve thousands of opioid-related suits filed against them. A government source close to the negotiations tells NPR that Purdue Pharma, Johnson & Johnson, Endo International and Allergan are looking to cut deals.

Updated at 7:04 p.m. ET

An Oklahoma judge has ruled that drugmaker Johnson & Johnson helped ignite the state's opioid crisis by deceptively marketing painkillers, and must pay $572 million to the state.

Oklahoma sought $17.5 billion, blaming Johnson & Johnson for fueling the crisis that has claimed the lives of more than 6,000 people in the state.

columbus.gov

The City of Columbus has filed a lawsuit against three drug manufacturers, five distributors and three individuals the city council president calls 'opinion leaders' for their alleged roles in the opioid crisis.

Ohio Public Radio

Republican Ohio Attorney General Mike DeWine has filed a lawsuit against five major drug companies, saying they have contributed to the opioid epidemic.

As Ohio's heroin overdose epidemic nears a record high in deaths, lobbyists representing prescription drug makers poured more than 3.5 million into Ohio political coffers over the last decade.

Dublin-based Cardinal Health will buy a Michigan-based pharmaceutical distributor called The Harvard Drug Group for 1.12 billion dollars.

Ohio Gets Share Of Settlement With Drug Maker

Nov 5, 2013

Ohio's Medicaid program will receive 52.7 million dollars from the newly-announced 2.2 billion dollar national settlement with Johnson & Johnson and a subsidiary.